Context Therapeutics Inc. · NASDAQ:CNTX
Context Therapeutics — Investor Presentation (November 2022)
28 slides from Context Therapeutics's investor presentation, Nov 9, 2022
Slide 1: Corporate Presentation: Advancing Medicines for Female Cancers
November 2022 Corporate Presentation Advancing Medicines for Female Cancers
Slide 2: Important Notice and Disclaimers
Important Notice and Disclaimers Except for statements of historical fact, any information contained in this presentation may be a forward-looking statement that reflects the Company’s current views about future events and are subject to risks, uncertainties, assumptions and changes in circumstances
Slide 3: Context Therapeutics Overview
Context Therapeutics Overview Context Therapeutics Inc. - November 20223 Company Overview Focus on Women’s Oncology • Unmet clinical need in breast, ovarian, and endometrial cancers ONA-XR oral PR antagonist • ONA-XR is a novel, potentially first-in-class progesterone receptor (PR) antagonist • Endo
Slide 4: Unmet Need in Female Cancers
Unmet Need in Female Cancers Prevalence of Metastatic Female Cancers in EU5, Japan, and US Company Overview Context Therapeutics Inc. - November 20224 Source: secondary epidemiologic estimates, 2020 estimates 89,000 28,000 25,000 104,000 30,000 28,000 35,000 12,000 11,000 - 50,000 100,000 150,000 20
Slide 5: Pipeline
Pipeline Context Therapeutics Inc. - November 20225 1 Tyligand Biosciences Ltd licensed rights to ONA-XR in China, HK, Macau * Investigator Sponsored Trial Cancer Clinical Indication Preclinical Phase 1 Clinical Phase 2 Clinical Milestones ONA-XR (PR antagonist)1 Breast Cancer 2L/3L ER+,PR+,HER2- Co
Slide 6: ONA-XR Progesterone Receptor Antagonist
ONA-XR Progesterone Receptor Antagonist 6 Context Therapeutics Inc. - November 2022
Slide 7: Onapristone Extended Release (ONA-XR)
Onapristone Extended Release (ONA-XR) Context Therapeutics Inc. - November 20227 ONA-XR Program Mechanism of Action • Onapristone (ONA) is a progesterone receptor (PR) antagonist that suppresses PR oncogenic signaling • PR oncogenic signaling is associated with breast, ovarian, and endometrial cance
Slide 8: Mechanism of Action
Mechanism of Action Blocking cancer growth by combining antiestrogen and antiprogestin therapies Context Therapeutics Inc. - November 20228 ONA-XR Program Cell Survival Stemness Immune Evasion Proliferation Estrogen Progesterone Cancer Driver Stimulus Cancer Growth and MetastasisOutcome Antiestrogen
Slide 9: PR Regulates Cancer Drivers of Stemness and Immune Evasion
PR Regulates Cancer Drivers of Stemness and Immune Evasion ONA-XR Program Context Therapeutics Inc. - November 20229 PR Promotes Cancer Cell Stemness and Metasteses1 PR Restricts Immune Recognition of Cancer Cells2 ** 67NR-PR Tumor Volume • Antiprogestins onapristone and mifepristone inhibited tumor
Slide 10: Completed Clinical Trials
Completed Clinical Trials Summary of select clinical trials evaluating onapristone with IR or XR formulation Onapristone Treatment Stage Patients (n) Clinical Indication Prior Treatments Median (range) Biomarker Data IR (100 mg QD) Ph 2 19 Breast Cancer First line (1L) advanced or metastatic Hormone
Slide 11: Key Ongoing Clinical Trials
Key Ongoing Clinical Trials ONA-XR Program Context Therapeutics Inc. - November 202211 Treatment Stage Patients (n) Clinical Indication Biomarker Key Inclusion and Exclusion Criteria Collaborator Data Update1 ONA-XR + Anastrozole Ph 2 25 Endometrial Cancer PR+ • Must have received at least one prior
Slide 12: ONA-XR Recurrent PR+ Endometrial Cancer
ONA-XR Recurrent PR+ Endometrial Cancer 12 Context Therapeutics Inc. - November 2022
Slide 13: Endometrial Cancer
Endometrial Cancer • Endometrial cancer is the 4th most common cancer in women ̶ Endometrial cancer is on the rise and is linked to obestiy1,2 ̶ ~13,000 patient deaths per year in the US3 ̶ Market is projected to grow from $1.5bn in 2020 to $5.1bn in 20295 • Hormone signaling is a driver of endometr
Slide 14: Endometrial Cancer Patient Treatment Landscape
Endometrial Cancer Patient Treatment Landscape1 ONA-XR in PR+ Endometrial Cancer Context Therapeutics Inc. - November 202214 Primary Adjuvant 1L Maintenance 2L 3L • Chemotherapy• Chemotherapy • Radiotherapy • Watchful waiting • Chemotherapy • Lenvima + Keytruda • CPI (MSI-H, dMMR) • Antiestrogen • C
Slide 15: ONA-XR + Anastrozole in PR+ Endometrial Cancer
ONA-XR + Anastrozole in PR+ Endometrial Cancer1 • Ongoing Phase 2 Trial ̶ Investigator-initiated, open label, multi-center, trial evaluating ONA-XR 50 mg BID in combination with the antiestrogen anastrozole 1 mg QD administered orally to treat women with ER+/PR+ endometrial adenocarcinoma who have r
Slide 16: Benchmarking Against Single Agents
Benchmarking Against Single Agents ONA-XR + Anastrozole ONA-XR Anastrozole Trial Schilder (ongoing)1 Cottu 20182 PARAGON 20193 Patients (n) 12 (9 evaluable) 12 54 Lines of Prior Chemotherapy, n (%) 1 ≥2 8 (66) 4 (33) 4 (33) 8 (66) 50 (93) 4 (7) Treatment free interval (TFI) ≥6 months, n (%) 4 (33) 1
Slide 17: CLDN6xCD3 Bispecific Antibody Program
CLDN6xCD3 Bispecific Antibody Program 17 Context Therapeutics Inc. - November 2022
Slide 18: Claudin (CLDN6) is an Emerging Oncology Target
Claudin 6 (CLDN6) is an Emerging Oncology Target Opportunity • CLDN6 is a tumor-specific protein that is present at high surface density across adult and pediatric cancers1 • CLDN6 is expressed at very low levels or absent from normal adult tissue Challenge • CLDN6 antigen is conformationally-depend
Slide 19: CLDN6 is Selectively Expressed on Cancer Cells
CLDN6 is Selectively Expressed on Cancer Cells CLDN6 Program Context Therapeutics Inc. - November 202219 (a) adrenal gland, (b) fallopian tube, (c) kidney, (d) liver, (e) thyroid, (f) prostate, (g) esophagus, (h) stomach, (i) colon, (j) cerebrum, (k) cerebellum, (l) spinal cord. (m) thymus, (n) sple
Slide 20: CLDN6 Has the Potential to Reach a Large Patient Population
CLDN6 Has the Potential to Reach a Large Patient Population ~62,500 patients per year in the US only in Relapse/Refractory Setting CLDN6 Program Context Therapeutics Inc. - November 202220 Selected Cancer indications Incidence R/R Incidence CLDN6 Positive Patient Population Based on R/R Incidence Te
Slide 21: Context Antibodies Display High Selectivity for CLDN6
Context Antibodies Display High Selectivity for CLDN61 CLDN6 Program Context Therapeutics Inc. - November 202221 1 Rucker, AACR Annual Meeting 2022 IM171 -10 -9 -8 -7 -6 0 50,000 100,000 150,000 Log [MAb], M M e a n F lu o re s c e n c e IM302 -10 -9 -8 -7 -6 0 50,000 100,000 150,000 Log [MAb], M M
Slide 22: Development of Selective and Potent CLDN6 Bispecific Antibodies
Development of Selective and Potent CLDN6 Bispecific Antibodies CLDN6 Program 1 Rucker, AACR Annual Meeting 2022 Context Therapeutics Inc. - November 2022 22 Bispecific antibodies retain high CLDN6 specificity1 Bispecifics induce robust T-cell dependent cytotoxicity1 • A diverse set of bispecific fo
Slide 23: Corporate
Corporate 23 Context Therapeutics Inc. - November 2022
Slide 24: Experienced Leadership Team
Corporate Experienced Leadership Team • Experienced team with deep oncology experience • Our CMO led the clinical development of multiple blockbuster drugs for female cancers, including Kisqali, Arimidex, and Afinitor • Our management team is supported by a Board with strong public company operating
Slide 25: Recent and Key Anticipated Milestones
Recent and Key Anticipated Milestones ONA-XR 1H 2022 2H 2022 2023 2024 Breast – AACR preclinical update Breast – ELONA trial initiation Endometrial – Phase 2 initial data Granulosa Cell – Phase 2 initial data Breast – SMILE trial initial Phase 2 data Breast – ELONA trial Phase 1b data Context Therap
Slide 26: Investment Highlights
Corporate Investment Highlights Female Cancers Large Unmet Need Progesterone Receptor and Claudin 6 High-Value Targets Multiple Data Readouts in Q4 2022 Near-Term Milestones Deep Domain Experience, Track Record of Success Strong Team Expected Cash Runway into Q1 2024 Financial Strength Context Thera
Slide 27: Advancing Medicines for Female Cancers
ADVANCING MEDICINES FOR FEMALE CANCERS © CONTEXT THERAPEUTICS 2022
Slide 28: Appendix: Abbreviations
Appendix Abbreviations Context Therapeutics Inc. - November 202228 Clinical Trial Efficacy CBR (CR+PR+ SD ≥6 mos) Clinical benefit rate CR Complete response DCR (CR+PR+ SD) Disease control rate DoR Duration of response mPFS Median PFS ORR (CR+PR) Overall response rate PFS Progression free survival S
Context Therapeutics — Investor Presentation (November 2022) on 6ix